Results from a study published today in the American Journal of Infection Control (AJIC), suggest that a common type of N95 respirator can be safely reprocessed to augment supply during future epidemics. Researchers at Beth Israel Deaconess Medical Center and Massachusetts institute of Technology (MIT) reprocessed respirators using vaporized hydrogen peroxide (VHP), a standard decontamination approach, and found that the devices maintained their function and effectiveness on human subjects with up to 25 cycles of re-use.
N95 respirators are commonly used in hospitals worldwide to protect healthcare personnel from infectious pathogens. During the SARS-CoV-2 pandemic, healthcare facilities experienced shortages of the respirators, forcing personnel to re-use them or resort to less protective alternatives (e.g., facial masks).
“The findings from our study expand upon previous findings that VHP is a relatively safe method for reprocessing N95 respirators, and could help address shortages in future epidemics,” said Christina F. Yen, MD, infectious diseases physician who completed her healthcare epidemiology and infection control training at Beth Israel Deaconess Medical Center and the paper’s lead author. “It is important that we now find ways to scale and translate this capability to smaller hospitals and resource-limited healthcare settings that could benefit just as much – perhaps more – from this type of personal protective equipment reprocessing in future disaster scenarios.”
Dr. Yen and colleagues used VHP to serially decontaminate seven N95 respirators. After each VHP cycle, they conducted a series of qualitative and quantitative tests to evaluate both the function and effectiveness of the respirators on human subjects as compared to baseline. These tests comprised a user seal check (performed by subjects donning and doffing the respirators), qualitative and quantitative respirator fit testing, and filtration efficiency testing, which assesses the ability of the respirator to filter out particles.
Results published today in AJIC, the journal of the Association for Professionals in Infection Control and Epidemiology (APIC), show that even after 25 decontamination cycles there were no alterations to respiratory integrity or filtration efficiency among the seven N95 respirators the researchers evaluated. All met the primary endpoints of function and effectiveness, passing 25 user seal checks and eight quantitative and four qualitative fit tests, in addition to maintaining filtration efficiencies of 95% or above throughout the study. As compared to baseline filtration efficiencies of 99% for particles between 0.3-10 µm in diameter, filtration rates after VHP reprocessing cycles 20 and 25 for 0.3-10 diameter particles were 99.9% and 99.6%, respectively. These changes were not statistically significant (p=0.10 after cycle 20 and p=0.05 after cycle 25).
The researchers noted that successful, large-scale implementation of N95 respirator reprocessing requires planning and coordination, multidisciplinary teams to ensure disinfection efficacy and end-user safety, and significant logistical support.
“In order for reprocessing to be a realistic option for healthcare facilities, certain steps need to be taken,” Yen said. Examples of these steps include creating relationships between infection prevention, occupational health, environmental services, and other relevant functions within hospitals to facilitate implementation of appropriate technologies and advocating for the inclusion of personal protective equipment reprocessing in epidemic and pandemic planning.
“The findings from this study are encouraging and valuable, particularly given the N95 respirator shortage we experienced during the COVID-19 pandemic,” said Ann Marie Pettis, BSN, RN, CIC, FAPIC, and APIC 2021 president. “The results make clear that investing in VHP capabilities now could help to ensure equitable access to personal protective equipment during any future pandemic.”